CLYM · Climb Bio Inc
United States · RS rating 49 · As of 2026-11-03
| Price | 9.75 USD |
|---|---|
| 1-day change | +0.1% |
| RS rating (overall / 1M / 3M / 12M) | 49 / 32 / 29 / 98 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 29 / 37 / 15 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -36.8% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +45.4% |
| Market cap (USD) | $430.9M |